|
 |
|
|
events |
|
|
|
|
|
 |
Sep-13, 2006 |
|
|
|
|
|
May-18, 2006 |
|
|
|
|
|
May-09, 2006 |
|
|
|
|
|
May-11, 2005 |
|
|
|
|
|
April-25 to April-26, 2005 |
|
|
|
|
|
March-20, 2005 |
|
|
|
|
|
February-28, 2005 |
|
|
|
|
|
February-20 to February-22, 2005 |
|
|
|
|
|
February-17, 2005 |
|
|
|
|
|
October-31, 2004 |
|
|
|
|
|
June-14, 2004 |
|
|
|
|
|
May-13, 2004 |
|
|
|
|
|
May-09, 2004 |
|
|
|
|
|
April-06, 2004 |
|
|
|
|
|
Nov-11, 2003 |
|
|
|
|
|
Oct-31, 2003 |
|
|
|
|
|
Mar-27, 2003 |
|
|
|
|
|
Mar-27, 2003 |
|
|
|
|
|
Mar-14, 2003 |
|
|
|
|
|
Jan-30 to Feb-01, 2003 |
|
|
|
|
|
Sep-05, 2002 |
|
|
|
|
|
May-20, 2002 |
|
|
|
|
|
Feb-08, 2002 |
|
|
|
|
|
Oct-29 - Nov-01, 2001 |
|
|
|
|
|
Nov-22, 2001 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
Sep-13, 2006
American Chemical Society, 232nd National Meeting & Exposition, San Francisco / USA -
Dr. Kai Lamottke, General Manager of Bicoll Biotechnology (Shanghai) Co. Ltd. invited to present insights of the successful "Establishment of a Research & Development site in China" |
|
|
| Date: |
Wednesday, September-13, 2006 |
| Time: |
9:00 AM - 11:15 AM |
| Session: |
Division of Small Chemical Businesses | True Stories of Small Chemical Businesses |
| Location: |
San Francisco Marriott -- Pacific Room C, Oral
|
From the lab bench to the market, scientists will present new multidisciplinary research at the 232nd national meeting & exposition of the American Chemical Society (ACS). The American Chemical Society is the world's largest scientific society dedicated to a single discipline, with more than 158,000 members. The society will hold its 232nd national meeting & exposition in San Francisco, CA, from September 10-14, 2006. More than 12,500 scientists are expected to attend this meeting, with approximately 7,000 papers to be presented.
Dr. Kai Lamottke, General Manager of Bicoll Biotechnology (Shanghai) Co. Ltd. is invited to present insights of the successful "Establishment of a Research & Development site in China".
In 2001 the Bicoll Group implemented one of the first international biopharmaceutical R&D locations in China. The set-up phase of its R&D unit for drug discovery in Shanghai was completed exceptionally fast after one year. In 2005, only four years after the initial set-up, Bicoll Biotechnology (Shanghai) Co. Ltd. already doubled the size of its R&D locations.
Kai Lamottke will join practical lessons learned at the build-up process of Bicoll's centre for biopharmaceutical research & development:
Bicoll's business model is based on a dual concept with technology development, cooperation management and marketing functions in Munich and facilities for research and development located in Shanghai. Based on in-depth experience the lecture gives a careful analysis of the weaknesses and strengths of both locations and shows the resulting functional structure. |
|
|
|
|
|
|
|
May-18, 2006
ACHEMA 2006 / VBU - Gateway to International Markets / Biotechnology Markets in China, India and Eastern Europe - Dr. Christian Haug, Managing Director Bicoll GmbH and Chairman of Board of Directors Bicoll Biotechnology (Shanghai) Co. Ltd. will join insights of the successful "Establishment of a Research & Development site in China" |
|
 The P.R. China's national economy ascended to the sixth position worldwide in the last years - and the economic upturn seems to know no limits so far. Germany's trade relations to China are intensifying continuously and the Chinese market is offering a multitude of opportunities for German enterprises.
In 2001 the Bicoll Group implemented one of the first international biopharmaceutical R&D locations in China. The set-up phase of its R&D unit for drug discovery in Shanghai was completed exceptionally fast after only one year. In 2005, only four years after the initial set-up, Bicoll Biotechnology (Shanghai) Co. Ltd. already doubled the size of its R&D locations.
Dr. Christian Haug, managing director at Bicoll GmbH and Chairman of Board of Directors at Bicoll Biotechnology (Shanghai) Co. Ltd., will join practical lessons learned at the build-up process of Bicoll's centre for biopharmaceutical research & development.
Bicoll's business model is based on a dual concept with technology development, cooperation management and marketing functions in Munich and facilities for research and development located in Shanghai. Based on in-depth experience the lecture gives a careful analysis of the weaknesses and strengths of both locations and shows the resulting functional structure. |
|
|
|
|
|
|
May-09, 2006
LIFE SCIENCE PARTNERING - CHINA EUROPE, EUROPEAN FORUM I - Dr. Kai Lamottke, General Manager of Bicoll Biotechnology (Shanghai) Co. Ltd. invited as panel member of the Discussion Session II: "Accessing the Chinese Market: Do's & Don'ts for European Biotech Companies" |
|
| Life Science Partnering - China Europe, European Forum I |
| Date: |
09. Mai 2006 |
| Session: |
Discussion Session II: "Accessing the Chinese Market: Do's & Don'ts for European Biotech Companies"
11:45 - 13:00 |
| Location: |
Hilton Munich City Hotel, Rosenheimer Strasse 15, D-81667 Munich, Germany
|
In a half-day event, the first European Forum of the Life Sciences Partnering China & Europe Programme will bring together senior executives from pharma, large biotech and other firms looking for partnering, acquisition and licensing opportunities in China with senior representatives of leading Venture Capital funds and specialised consultants and advisors who are involved in or interested in the Chinese biotech industry.
In various public discussion sessions the aim of the event is to inform the audience about current situations, trends and challenges in the Chinese biotech market and potential cooperation within this geographic area.
Dr. Lamottke has considerable experience in international settings, in particular in Asia.
Dr. Lamottke is co-founder of Bicoll GmbH, Munich and Managing Director of the company. He is appointed as General Manager and member of the Board of Directors of Bicoll Biotechnology (Shanghai) Co. Ltd. since July 2001.
As founder and General Manager of the first Sino-German biopharmaceutical company Bicoll, Kai Lamottke gained special insights in the Chinese and global biotech and pharmaceutical market and built up an extensive network of commercial, academic and political connections in the life sciences and innovation sectors both in the P.R. China as well as internationally. |
|
|
|
|
|
|
|
May-11, 2005
Dr. Christian Haug talks at BIOPERSPECTIVES 2005, Wiesbaden/Germany - "Added value through know-how networks" |
|
Dr. Christian Haug, managing director at Bicoll GmbH and chairman of board of directors at Bicoll Biotechnology (Shanghai) Co. Ltd., is invited to give a talk at BIOPERSPECTIVES 2005. The BIOPERSPECTIVES 2005 will take place in Wiesbaden/Germany from May 10 to May 12, 2005 as central event for biotechnology in Middle Europe.
Dr. Haug's presentation "Added value through know-how networks" will be part of the congress program's special unit on co-operation models on May 11, 2005. Integration in academic research networks plays a key role for the evaluation of new trends in research and development. As the first Sino-German biopharmaceutical enterprise, Bicoll established co-operations with both German and Chinese research institutes. These intensive business relations and networks count as key for Bicoll's successful implementation in China. Dr. Haug will discuss some of Bicoll's international co-operation models that generate added value to both partners in such kind of network.
About Bicoll
The Bicoll Group is the first Sino-German biopharmaceutical enterprise and implemented one of the first international biopharmaceutical R&D locations in China. It was founded in 2001 with two legal entities: Bicoll GmbH in Munich, Germany, and Bicoll Biotechnology (Shanghai) Co. Ltd. in Zhangjiang High Tech Park, P.R. China. Technology development, cooperation management and marketing are functions in Munich, while facilities for research and development are located in Shanghai.
The company is specialized in high-tech natural product chemistry with a focus to make compounds from natural resources compatible with drug discovery systems in modern drug research.
Bicoll's primary products are optimized small molecule libraries for drug discovery in the biopharmaceutical industry. The libraries are tested and developed for fee and milestone payments in co-operations. They are customized to the target protein of the partner's indication field to provide a high success rate in screening and further development. The starting material is generated from endemic Asian plant resources.
Just four years after its foundation, the company already sells its R&D products to various strategic customers in the industry sectors pharma, nutraceuticals, crop protection and to leading research institutions.
Additionally, Bicoll follows up its own in-house development projects such as diabetes type II, and is currently building up expertise with a new approach in the area of oncology. |
|
|
|
|
|
|
April-25 to April-26, 2005
BIOTECHNOLOGIETAGE 2005, STUTTGART / GERMANY - Dr. Christian Haug joins the round table discussion "Going International" |
|
Biotechnology is one of the most important innovation fields of the 21st century and is developing to one of the most rapid growing lines of industry in Germany as well as worldwide. The German federal ministry of education and research (BMBF) is organizing the BIOTECHNOLOGIETAGE 2005 in Stuttgart / Germany as a platform to intensify business relations and networks within this field of business.
Dr. Christian Haug, managing director at Bicoll GmbH and chairman of board of directors at Bicoll Biotechnology (Shanghai) Co. Ltd., will join the round table discussion "Going International" on April 25, 2005.
In 2001 Bicoll implemented one of the first international biopharmaceutical R&D locations in China. The set-up phase of its R&D unit for drug discovery in Shanghai was completed exceptionally fast after only one year. Bicoll's business model is based on a dual concept with technology development, cooperation management and marketing functions in Munich and facilities for research and development located in Shanghai.
Dr. Haug was in charge of the set-up phase of Bicoll's R&D unit for drug discovery in Shanghai. This makes him an expert in the most essential factors of Bicoll's success record as well as mechanisms and instruments that allow a resource-effective remote management of both locations.
More information about the BIOTECHNOLOGIETAGE 2005 is available at www.bmbf.de/biotechnologietage
About Bicoll
The Bicoll Group is the first Sino-German biopharmaceutical enterprise. It was founded in 2001 with two legal entities: Bicoll GmbH in Munich, Germany, and Bicoll Biotechnology (Shanghai) Co. Ltd. in Zhangjiang High Tech Park, P.R. China. Technology development, cooperation management and marketing are functions in Munich, while facilities for research and development are located in Shanghai.
The company is specialized in high-tech natural product chemistry with a focus to make compounds from natural resources compatible with drug discovery systems in modern drug research.
Bicoll's primary products are optimized small molecule libraries for drug discovery in the biopharmaceutical industry. The libraries are tested and developed for fee and milestone payments in co-operations. They are customized to the target protein of the partner's indication field to provide a high success rate in screening and further development. The starting material is generated from endemic Asian plant resources.
Just three years after its foundation, the company already sells its research products to five strategic customers in the pharmaceutical industry and leading research institutions.
Additionally, Bicoll follows up its own in-house development projects such as diabetes type II, and is currently building up expertise with a new approach in the area of oncology. |
|
|
|
|
|
|
March-20, 2005
TV-Report on Bicoll in: "Boom Region Shanghai", TV documentary by Michael Wech, 3Sat TV Station |
|
| TV-Report on Bicoll in: "Boom Region Shanghai", TV documentary by Michael Wech, 3Sat TV Station - technology magazine "hitech", march 20st, 2005, 4:00 pm (GMT + 1:00) |
|
|
|
|
|
|
February-28, 2005
DECHEMA Conference Day: Research and Development in China - Dr. Christian Haug talks about "Set-up of a research location in Shanghai" |
|
The P.R. China's national economy ascended to the sixth position worldwide in the last years - and the economic upturn seems to know no limits so far. Germany's trade relations to China are intensifying continuously and the Chinese market is offering a multitude of opportunities for German enterprises.
Dr. Christian Haug, managing director at Bicoll GmbH and chairman of board of directors at Bicoll Biotechnology (Shanghai) Co. Ltd., was invited to give a talk at the DECHEMA Conference Day "Research and Development in China" that took place in Frankfurt, Germany on February 28, 2004.
The Bicoll Group implemented one of the first international biopharmaceutical R&D locations in China. The set-up phase of its R&D unit for drug discovery in Shanghai was completed exceptionally fast after only one year. Bicoll's business model is based on a dual concept with technology development, cooperation management and marketing functions in Munich and facilities for research and development located in Shanghai.
Experts from more than 70 German chemical and pharmaceutical industrial companies and research institutes were following Dr. Haug's documentation on the successful set-up of a research location in Shanghai. He explained the most essential factors of Bicoll's success record as well as mechanisms and instruments that allow a resource-effective remote management of both international locations.
For a copy of Dr. Haug's presentation, please contact haug@bicoll-group.com
About Bicoll
The Bicoll Group is the first Sino-German biopharmaceutical enterprise. It was founded in 2001 with two legal entities: Bicoll GmbH in Munich, Germany, and Bicoll Biotechnology (Shanghai) Co. Ltd. in Zhangjiang High Tech Park, P.R. China. Technology development, cooperation management and marketing are functions in Munich, while facilities for research and development are located in Shanghai.
The company is specialized in high-tech natural product chemistry with a focus to make compounds from natural resources compatible with drug discovery systems in modern drug research.
Bicoll's primary products are optimized small molecule libraries for drug discovery in the biopharmaceutical industry. The libraries are tested and developed for fee and milestone payments in co-operations. They are customized to the target protein of the partner's indication field to provide a high success rate in screening and further development. The starting material is generated from endemic Asian plant resources.
Just three years after its foundation, the company already sells its research products to five strategic customers in the pharmaceutical industry and leading research institutions.
Additionally, Bicoll follows up its own in-house development projects such as diabetes type II, and is currently building up expertise with a new approach in the area of oncology.
|
|
|
|
|
|
|
February-20 to February-22, 2005
TV-Report on Bicoll in: "Boom Region Shanghai", TV documentary by Michael Wech, Deutsche Welle World (Internet TV Station) |
|
Broadcasting information:
Internet TV Station "Deutsche Welle World" www.dw-world.de,
technology magazine "In Focus (English language) / Im Focus (German language) / Prisma (Spanish language)" |
|
February-20, 2005
03:30 pm Technology Magazine "Im Focus" (German)
06:30 pm Technology Magazine "In Focus" (English)
09:30 pm Technology Magazine "Prisma" (Spanish) |
|
February-21, 2005
03:30 am Technology Magazine "Im Focus" (German)
06:30 am Technology Magazine "In Focus" (English)
09:30 pm Technology Magazine "Im Focus" (German) |
|
February-22, 2005
00:30 am Technology Magazine "In Focus" (English)
02:30 am Technology Magazine "Prisma" (Spanish)
09:30 am Technology Magazine "Im Focus" (German)
12:30 pm Technology Magazine "In Focus" (English) |
|
| All times are given in UTC/GMT |
|
|
|
|
|
|
|
February-17, 2005
Interview with Dr. Kai Lamottke for "Dimensions: World of Science, Pills made in China", radio documentary by Nikolaus Scholz |
|
| Interview with Dr. Kai Lamottke for "Dimensions: World of Science, Pills made in China", radio documentary by Nikolaus Scholz, ORF radio station OE1 (Austria), 07:05 pm (GMT + 1:00) |
|
|
|
|
|
|
October-31, 2004
TV-Report on Bicoll in: "Boom Region Shanghai", TV documentary by Michael Wech, 3Sat TV Station |
|
|
 |
|
technology magazine "hitech",
October 31st, 2004, 4:00 pm (GMT + 1:00) |
|
|
|
|
|
|
|
June-14, 2004
Bicoll invited to present at "LMU Excellence International China - Growth Market for Global Player" |
|
The Bicoll Group (Munich/Shanghai) was invited to share its expertise in successful Sino-German business relations with experts and executives of diverse fields and lines of industry at the business meeting "Excellence International China - Growth Market for Global Player". The event was organized by the Ludwig-Maximilians-University, Munich/Germany and was part of the university's "Professional Development" series.
The P.R. China's national economy ascended to the sixth position worldwide in the last years - and the economic upturn seems to know no limits so far. Germany's trade relations to China are intensifying continuously and the Chinese market is offering a multitude of opportunities for German as well as international enterprises.
The Bicoll Group implemented one of the first international biopharmaceutical R&D locations in China. The set-up phase of its R&D unit for drug discovery in Shanghai was completed exceptionally fast after only one year. Dr. Heinrich M. Arnold, co-founder and shareholder of Bicoll, presented the company's business model and explained the most essential factors of Bicoll's success record with the audience. High attention received his description of mechanisms and instruments that allow a resource-effective remote management of both international locations.
About Bicoll
The Bicoll Group is the first Sino-German biopharmaceutical enterprise. It was founded in 2001 with two legal entities: Bicoll GmbH in Munich, Germany, and Bicoll Biotechnology (Shanghai) Co. Ltd. in Zhangjiang High Tech Park, P.R. China. Technology development, cooperation management and marketing are functions in Munich, while facilities for research and development are located in Shanghai.
The company is specialized in high-tech natural product chemistry with a focus to make compounds from natural resources compatible with drug discovery systems in modern drug research.
Bicoll's primary products are optimized small molecule libraries for drug discovery in the biopharmaceutical industry. The libraries are tested and developed for fee and milestone payments in co-operations. They are customized to the target protein of the partner's indication field to provide a high success rate in screening and further development. The starting material is generated from endemic Asian plant resources.
Just three years after its foundation, the company already sells its research products to five strategic customers in the pharmaceutical industry and leading research institutions.
Additionally, Bicoll follows up its own in-house development projects such as diabetes type II, and is currently building up expertise with a new approach in the area of oncology.
|
|
|
|
|
|
|
May-13, 2004
Dr. Christian Haug talks at ACHEMASIA 2004 in Beijing about "Accessing privileged chemical structures for novel pharmaceuticals" |
|
 Dr. Christian Haug, managing director at Bicoll GmbH and chairman of board of directors at Bicoll Biotechnology (Shanghai) Co. Ltd., was invited to give a talk at ACHEMASIA 2004. This 6th International Exhibition-Congress on Chemical Engineering and Biotechnology took place in Beijing, P.R. China from May 11 to May 15, 2004. Experts from international industrial companies and research institutes were following Dr. Haug's presentation "Accessing privileged chemical structures for novel pharmaceuticals" at the congress program's special business meeting on biotechnology on May 13. Dr. Haug shared aspects about Bicoll's successful business model on drug development using biological active natural compounds with leading scientists and industrialists from all over the world. Natural products are among the leading sources for delivering new pharmaceuticals. The worldwide topselling drug, Pfizer's Lipitor, with annual sales of nearly 10 Billion US$, has been developed based on the findings of a natural product. Bicoll's unique technology and expertise in drug discovery and development are aiming to produce further success stories based on natural products - among them might be the next Lipitor.
About Bicoll
The Bicoll Group is the first Sino-German biopharmaceutical enterprise. It was founded in 2001 with two legal entities: Bicoll GmbH in Munich, Germany, and Bicoll Biotechnology (Shanghai) Co. Ltd. in Zhangjiang High Tech Park, P.R. China. Technology development, cooperation management and marketing are functions in Munich, while facilities for research and development are located in Shanghai.
The company is specialized in high-tech natural product chemistry with a focus to make compounds from natural resources compatible with drug discovery systems in modern drug research.
Bicoll's primary products are optimized small molecule libraries for drug discovery in the biopharmaceutical industry. The libraries are tested and developed for fee and milestone payments in co-operations. They are customized to the target protein of the partner's indication field to provide a high success rate in screening and further development. The starting material is generated from endemic Asian plant resources.
Just three years after its foundation, the company already sells its research products to five strategic customers in the pharmaceutical industry and leading research institutions.
Additionally, Bicoll follows up its own in-house development projects such as diabetes type II, and is currently building up expertise with a new approach in the area of oncology.
|
|
|
|
|
|
|
May-09, 2004
Dr. Christian Haug invited to talk at the 1st Biosciences Alumni Network China |
|
 Dr. Christian Haug, managing director at Bicoll GmbH and chairman of board of directors at Bicoll Biotechnology (Shanghai) Co. Ltd, was invited to give a presentation about Bicoll's built-up process in Shanghai at the 1st Biosciences Alumni Network China meeting. Dr. Haug shared aspects about the challenges in establishing pharmaceutical research through a biotech company in China with more than 100 participants from academia and industry. Bicoll's practical experience as the first Sino-German biotechnology company attracted huge interest among the attendees. The Biosciences Alumni Network China meeting was held in Shanghai from May 07 till May 09, 2004 and organized by the German Academic Exchange Service (DAAD), together with the China National Centre for Biotechnology Development (CNCBD), and its counterpart the German Federal Ministry for Education and Research (BMBF). Dr. Haug was the first German exchange researcher in the P.R. China to be supported through a DAAD stipend "Biosciences".
About Bicoll
The "Bicoll Group" is the first Sino-German biopharmaceutical enterprise. It was founded in 2001 with two legal entities: Bicoll GmbH in Munich, Germany, and Bicoll Biotechnology (Shanghai) Co. Ltd. in Zhangjiang High Tech Park, P.R. China. Technology development, cooperation management and marketing are functions in Munich, while facilities for research and development are located in Shanghai.
The company is specialized in high-tech natural product chemistry with a focus to make compounds from natural resources compatible with drug discovery systems in modern drug research.
Bicoll's primary products are optimized small molecule libraries for drug discovery in the biopharmaceutical industry. The libraries are tested and developed for fee and milestone payments in co-operations. They are customized to the target protein of the partner's indication field to provide a high success rate in screening and further development. The starting material is generated from endemic Asian plant resources.
Just three years after its foundation, the company already sells its research products to five strategic customers in the pharmaceutical industry and leading research institutions.
Additionally, Bicoll follows up its own in-house development projects such as diabetes type II, and is currently building up expertise with a new approach in the area of oncology. |
|
|
|
|
|
|
April-06, 2004
"Managerial and financial aspects about recent trends in the interaction of biotech and pharma industries" - a lecture hold by Dr. Heinrich Arnold |
|
 Dr. Heinrich M. Arnold, head of business affairs at Bicoll, gave a lecture about "Managerial and financial aspects about recent trends in the interaction of biotech and pharma industries" in front of Master students at the Sino-German College of the Tongji University, P.R. China. The lecture was given following an invitation by Prof. Wei Yi, Dresdner Bank Chair for Financial Management. Aspects covered were the current trends in the interaction between Biotech and big Pharma companies in research and development, managerial and financial aspects about in-licensing and in-house drug discovery and development, and a brief outlook.
Very rewarding for the presenter was the warm welcome by the professor and the students and a very rich discussion after the lecture. Some impression of the lecture is reflected in the digital picture attached.
About Bicoll
The "Bicoll Group" is the first Sino-German biopharmaceutical enterprise. It was founded in 2001 with two legal entities: Bicoll GmbH in Munich, Germany, and Bicoll Biotechnology (Shanghai) Co. Ltd. in Zhangjiang High Tech Park, P.R. China. Technology development, cooperation management and marketing are functions in Munich, while facilities for research and development are located in Shanghai.
The company is specialized in high-tech natural product chemistry with a focus to make compounds from natural resources compatible with drug discovery systems in modern drug research.
Bicoll's primary products are optimized small molecule libraries for drug discovery in the biopharmaceutical industry. The libraries are tested and developed for fee and milestone payments in co-operations. They are customized to the target protein of the partner's indication field to provide a high success rate in screening and further development. The starting material is generated from endemic Asian plant resources.
Just three years after its foundation, the company already sells its research products to five strategic customers in the pharmaceutical industry and leading research institutions.
Additionally, Bicoll follows up its own in-house development projects such as diabetes type II, and is currently building up expertise with a new approach in the area of oncology. |
|
|
|
|
|
|
Nov-11, 2003
Lecture Series "Innovation Management" - School of Business, University of Munich / Germany - "Radical Technological Change", a lecture held by Dr. Heinrich Arnold |
|
Innotec - the Institute for Innovation Research, Technology Management, and Entrepreneurship at the School of Business, University of Munich, Germany invited Dr. Heinrich M. Arnold, head of business affairs at Bicoll, to give a lecture within the institute's lecture series for innovation management.
Heinrich Arnold gave an overview of different types of technological changes and described methods for their identification. The lecture monitored the current status of research on success factors how firms can overcome technological change.
Dr. Arnold also presented his own research on this subject that enhances and partially challenges classical teaching in the management of technology. Much of his research is available as a book "technology shocks" (www.technologyshocks.de) published recently by Springer in the Physica-Verlag series "Contributions to management science".
The observations apply to the biotechnology industry as well. The Biotech industry itself can be seen as the result of radical technological change that was brought about by genomics/ proteomics combined with high performance computing and process automation combined with miniaturization.
About Bicoll
The Bicoll group is an international biopharmaceutical enterprise with its head office in Munich, Germany, and a research and development site in Shanghai, P.R. China.
Bicoll's successful strategy for modern drug design is based on superior compounds for lead generation derived from plants.
Bicoll's advances in natural products technology enabled the company to overcome the classical drawbacks of natural product chemistry while at the same time exploiting the high potential of plants for drug development. The company's proprietary core technologies BIFRAC N and BIPRESELECT are specially engineered to accelerate the development process of new drug candidates based on plants. BIFRAC N is a high-resolution isolation and separation system to detect biologically active compounds. Through BIPRESELECT, the company can narrow in on pre-defined ADME criteria. Thus Bicoll is able to sort out compounds early, that have low probability of becoming drug candidates and which would otherwise block the drug development pipeline. Bicoll's technology shortens the time-consuming and expensive process of lead discovery and pre-clinical studies by around one third and reduces the failure rate in the drug development process.
|
|
|
|
|
|
|
Oct-31, 2003
Seminar "Innovative Processes in Biotechnology", Munich / Germany - "In-house versus In-licensing" - a lecture held by Dr. Heinrich Arnold |
|
Dr. Heinrich M. Arnold, head of business affairs of Bicoll, was invited speaker at the two-day seminar "Innovative Processes in Biotechnology" organized by Innotec - the Institute for Innovation Research, Technology Management, and Entrepreneurship at the School of Business, University of Munich, Germany.
The current squeeze in pharma research creates a dramatic need for a lost-cost approach to rapidly marketable results. With his lecture, Dr. Arnold showed the participants how the pharmaceutical industry is currently changing its business strategy from in-house activities to in-licensing. For the majority of companies, this results in much faster positive cash flows from drug development. Against the setting of these facts, biotechnology enterprises will more and more get invited to cooperate with the pharmaceutical industry.
Dr. Arnold gave an overview of Bicoll's modern approach to innovative drug development - drug discovery based on natural products and how it can overcome the current hurdles in modern drug development.
About Bicoll
The Bicoll group is an international biopharmaceutical enterprise with its head office in Munich, Germany, and a research and development site in Shanghai, P.R. China.
Bicoll's successful strategy for modern drug design is based on superior compounds for lead generation derived from plants.
Bicoll's advances in natural products technology enabled the company to overcome the classical drawbacks of natural product chemistry while at the same time exploiting the high potential of plants for drug development. The company's proprietary core technologies BIFRAC N and BIPRESELECT are specially engineered to accelerate the development process of new drug candidates based on plants. BIFRAC N is a high-resolution isolation and separation system to detect biologically active compounds. Through BIPRESELECT, the company can narrow in on pre-defined ADME criteria. Thus Bicoll is able to sort out compounds early, that have low probability of becoming drug candidates and which would otherwise block the drug development pipeline. Bicoll's technology shortens the time-consuming and expensive process of lead discovery and pre-clinical studies by around one third and reduces the failure rate in the drug development process.
|
|
|
|
|
|
|
Mar-27, 2003
Chamber of Industry and Commerce, Pfalz: Presentation of Bicoll's unique business model in Shanghai / P.R. China |
|
Dr. Kai Lamottke, managing director of Bicoll, was invited by the Chamber of Industry and Commerce, Pfalz (IHK Pfalz) on the occasion of the IHK's event "Biotechnology and Medicinal Technology in the P.R. China - Chances for German Enterprises". Dr. Lamottke gave a presentation as a case study on the chances and risks of the recently completed build-up process of the first German-Sino biotechnology company located in Shanghai. A major part of Bicoll's proprietary technology platform could be implemented at the Shanghai laboratories within one year only. Until 2005, Bicoll Biotechnology (Shanghai) Co. Ltd. is planning to extend the company's research and development location from currently 15 to over 50 employees.
The Bicoll group is an international pharmaceutical enterprise with its head office in Munich, Germany, and its research and development location in Shanghai, P.R. China.
Bicoll's successful strategy for modern drug design is based on the company's proprietary technology platform. Its two core technologies BIFRAC N and BIPRESELECT are specially engineered to accelerate the development process of new drug candidates based on plants. Bicoll's advances in natural products technology enabled the company to overcome the classical drawbacks of natural product chemistry while at the same time exploiting the high potential of plants for drug development. BIFRAC N is a high resolution isolation and separation system to detect biologically active compounds. Through BIPRESELECT, the company can narrow in on pre-defined ADME criteria. Thus Bicoll is able to sort out compounds early, that have low probability of becoming drug candidates and which would otherwise block the drug development pipeline. Bicoll's technology shortens the time-consuming and expensive process of lead discovery and pre-clinical studies by around one third and reduces the failure rate in the drug development process.
|
|
|
|
|
Get the pdf-file here: (30 KB, language: German)
If you would like to read more about Bicoll's participation at this event in the press, find an article here:
> transkript 5/03, page 50.
|
|
|
|
|
|
|
|
Mar-27, 2003
31st German Venture Market "Biotech, Nanotech, Pharmaceutics & Chemicals", Frankfurt - Special Feature ASIA: Presentation of Bicoll's successful business model in Shanghai / P.R. China |
|
Dr. Heinrich M. Arnold, head of business affairs of Bicoll, was speaker at the 31st German Venture Market "Biotech, Nanotech, Pharmaceutics & Chemicals". Dr. Arnold was invited by CONTINUA, the single private organizer of venture capital conferences on the German-speaking market, to present Bicoll's unique business model at the event's special feature on the Asian market.
The current squeeze in pharma research creates a dramatic need for a lost-cost approach to rapidly marketable results. With his lecture "Riding the downward wave - a recession business model", Dr. Arnold, showed the more than 80 conference participants from venture capitalists to pharmaceutical and biotech executives, how Bicoll's business model can overcome the current hurdles in modern drug development.
The Bicoll group is an internationally orientated biopharmaceutical enterprise with its head office in Munich, Germany, and its research and development location in Shanghai, P.R. China.
Bicoll's successful strategy for modern drug design is based on the company's proprietary technology platform. Its two core technologies BIFRAC N and BIPRESELECT are specially engineered to accelerate the development process of new drug candidates based on plants. Bicoll's advances in natural products technology enabled the company to overcome the classical drawbacks of natural product chemistry while at the same time exploiting the high potential of plants for drug development. BIFRAC N is a high resolution isolation and separation system to detect biologically active compounds. Through BIPRESELECT, the company can narrow in on pre-defined ADME criteria. Thus Bicoll is able to sort out compounds early, that have low probability of becoming drug candidates and which would otherwise block the drug development pipeline. Bicoll's technology shortens the time-consuming and expensive process of lead discovery and pre-clinical studies by around one third and reduces the failure rate in the drug development process.
|
|
|
|
|
|
|
Mar-14, 2003
Round-table discussion of decision makers in development policy and foreign trade - Shanghai, P.R. China |
|
Decision makers of German non-profit organisations doing business in China were invited by the German Consulate in Shanghai to participate in a round-table discussion for development policy and its main focus in the up-coming two years. The event took place in Shanghai, P.R. China and followed the annual meeting of the German Federal Ministry of Economic Cooperation and Development and the Chinese Ministry of Foreign Trade and Economic Cooperation (MOFTEC) held in Beijing. Bicoll was invited as the only private enterprise and represented through Dr. Christian Haug, managing director of Bicoll GmbH, because of its biodiversity conservation projects. In several open discussions Dr. Haug shared insides and aspects of the built-up process in the P.R. China with participants from the German Federal Ministry for Economic Cooperation and Development, the German consulate general in Shanghai, the German embassy in Beijing, the German Development Cooperation (GTZ) and several other organisations involved in economic cooperation and development.
In this context, Dr Haug emphasized the necessity to develop business models that link economic gain and the protection of biodiversity. Bicoll is one of the few examples where a company operates on the principles and guidelines of the 1992 Rio Convention and the 2002 Bonn Guidelines on the protection of biodiversity.
About Bicoll
The "Bicoll Group" is the first Sino-German biopharmaceutical enterprise. It was founded in 2001 with two legal entities: Bicoll GmbH in Munich, Germany, and Bicoll Biotechnology (Shanghai) Co. Ltd. in Zhangjiang High Tech Park, P.R. China. Technology development, cooperation management and marketing are functions in Munich, while facilities for research and development are located in Shanghai.
The company is specialized in high-tech natural product chemistry with a focus to make compounds from natural resources compatible with drug discovery systems in modern drug research.
Bicoll's primary products are optimized small molecule libraries for drug discovery in the biopharmaceutical industry. The libraries are tested and developed for fee and milestone payments in co-operations. They are customized to the target protein of the partner's indication field to provide a high success rate in screening and further development. The starting material is generated from endemic Asian plant resources.
Just three years after its foundation, the company already sells its research products to five strategic customers in the pharmaceutical industry and leading research institutions.
Additionally, Bicoll follows up its own in-house development projects such as diabetes type II, and is currently building up expertise with a new approach in the area of oncology.
|
|
|
|
|
|
|
January-30 to February-01, 2003
"Biosciences" meeting of the German Academic Exchange Service (DAAD): Dr. Christian Haug lecturing about "parallel synthetic modification of natural products" |
|
Dr. Christian Haug, managing director of Bicoll GmbH, was invited by the German Academic Exchange Service (DAAD) to lecture about parallel synthetic modification of natural products as modern approach in drug discovery. In addition he was coordinating the workshop "biochemistry and analytical methods". More than 70 scholarship holders and alumni of the DAAD were meeting in Berlin to attend the DAAD's special program "Biosciences". Dr. Haug was the first German exchange researcher in the P.R. China to be supported through the DAAD stipend "Biosciences".
The Bicoll group is an internationally orientated biopharmaceutical enterprise with a headquarters office in Munich, Germany, and its research and development location in Shanghai, P.R. China.
Bicoll's competencies include natural product chemistry as well as combinatorial chemistry, structural biology, screening techniques, own developed novel deconvolution techniques, isolation strategies and structural elucidation. Bicoll's successful strategy for modern drug design is based on the company's proprietary technology platform. Its two core technologies BIFRAC N and BIPRESELECT shorten the time-consuming and expensive process of lead discovery and pre-clinical studies by around one third.
|
|
|
|
|
Get the pdf-file here: (330 KB, language: German)
If you would like to read more about the "Biosciences" meeting you can find an article here:
> DAAD Letter Hochschule und Ausland, Nr. 1 April 2003, Trio Verlag Königswinter, page 25
|
|
|
|
|
|
|
|
Sep-05, 2002
Dr. Christian Haug, Bicoll GmbH, invited to talk at the AnalytikaChina 2002-Symposium, Shanghai |
|
On the occasion of the first AnalyticaChina, the German Centre Shanghai, invited Dr. Christian Haug, Chairman of Board of Directors of Bicoll Biotechnology (Shanghai) Co. Ltd., to participate in a round table discussion for representatives of over 30 German companies attending the fair. Dr. Haug also gave a presentation about Bicoll's build-up process in Shanghai and the chances and risks of the foundation of a company and its practical experience in the P.R. China.
The Bicoll group is an internationally orientated biopharmaceutical enterprise with a headquarters office in Munich, Germany, and its research and development location in Shanghai, P.R. China.
Bicoll recently successfully completed the Chinese company's build-up process in Zhangjiang Hi-Tech Park in Shanghai. The prompt implementation of its proprietary technology platform for modern drug development could be succeeded within one year only. First products have already been launched into exclusive co-operations and partnerships. Within the next three years, Bicoll Biotechnology (Shanghai) Co. Ltd. is planning to extend the company's research and development location to over 50 employees.
|
|
|
|
|
|
|
May-20, 2002
Lecture series at the Hainan Normal College, P.R. China – initiated by Bicoll and the German Investment and Development Company (DEG) |
|
Bicoll and the German Investment and Development Company (DEG) as an initiator of a lecture series related to modern biotechnology at the Hainan Normal College, P.R. China. Bicoll and the DEG initiated their first seminar series at the Hainan Normal College, P.R. China. Bicoll's experts gave an overview on the hottest topics in modern drug discovery:
- "Evolutionary optimised small molecules as a tool fighting against diseases", Prof. Dr. Yang Ye
- "Understanding general mechanism of the mode of action to modulate cell metabolism: Molecular Recognition of small molecule ligands", Dr. Kai Lamottke
- "Targeting skin cancer blocking related proteins helps to save life", Dr. Jun Xie.
For years now, the Chinese government has encouraged universities and research institutions to increase their exchange of ideas and concepts with international institutions and companies.
Through its seminar series Bicoll supports education at specially selected universities. Furthermore, Bicoll is funding a unique educational program to train Chinese students in fields of mutual interest.
About Bicoll
Bicoll was founded in December 2000 as a unique German-Sino start-up biotech company and provides an innovative, flexible and fast concept for modern drug research. By combining research in combinatorial chemistry, screening techniques, natural product chemistry and synthesis, Bicoll's mission is to accelerate the developing process of new drug candidates.
|
|
|
|
|
|
|
Feb-08, 2002
Presentation of Bicoll's innovative concept of modern drug research at the Technical University, Munich, Germany |
|
Bicoll invited to present their innovative concept of modern drug research at the Technical University, Munich, Germany
The research group of Prof. Dr. Thorsten Bach, TU Munich, Germany invited Dr. Kai Lamottke, General Manager of Bicoll, to give a speech ("Bicoll Evolution has the solution") on the company's innovative R&D process. The process enables Bicoll to develop new drugs by an order of magnitude faster and more efficient than the conventional processes used today.
Prof. Bach's research group is specialising in modern, cutting-edge synthesis of natural and biological active compounds as well as the optimization of structure-effect-relations through synthesis. Additionally, the group is working on the development of new synthetic methods.
Refs.: Prof. Bach's research group
About Bicoll
Bicoll was founded in December 2000 as a unique German-Sino start-up biotech company.
Today, in modern drug development, most companies cannot satisfy the continuous growth in demand of new, high-quality active molecules addressing newly identified drug targets. Bicoll solves this bottleneck requirement with the invention of an innovative, flexible and fast concept that will be able to speed up modern drug discovery, selecting highly qualified small molecules for further development. |
|
|
|
|
|
|
Oct-29 - Nov-01, 2001
Second German-Chinese High-Tech Dialogue Forum, Beijing, P.R. China |
|
Bicoll attended the Second German-Chinese High-Tech Dialogue Forum in Beijing
Within the changing international landscape of modern drug discovery, Bicoll is a forerunner in the Chinese biotech scene. For the Second German-Chinese High-Tech Dialogue Forum initiated by the German and Chinese governments - Bicoll's Managing Director Dr. Lamottke and Deputy General Manager Dr. Xie were invited to represent Bicoll as one of the rare German biotechnology companies that already has an R&D site in China. The importance of the biotech industry in both countries was honoured by the speakers: the German Minister of Economy Dr. Müller, the German Chancellor Mr. Schröder, the Chinese Prime Minister Rongji Zhu and 10 additional Chinese Ministers. In addition to the state representatives, several CEOs of major companies from both countries (e.g. Deutsche Telekom AG, Siemens AG and Bayer AG on the German side) joined the Forum, to discuss further trends in telecommunication, engineering and biotechnology.
Today, in modern drug development, most companies cannot satisfy the continuous growth in demand of new, high-quality active molecules addressing newly identified drug targets. Bicoll solves this bottleneck requirement with the invention of an innovative, flexible and fast concept that will be able to speed up modern drug discovery by selecting highly qualified small molecules for further development.
|
|
 |
|
Morphosys' CSO v. Rüden (left)
together with the Bicoll delegation in Beijing |
|
|
About Bicoll
Bicoll was founded in December 2000 as a unique German-Sino start-up biotech company. By combining research in combinatorial chemistry, screening techniques, natural product chemistry and synthesis Bicoll's mission is to accelerate the developing process of new drug candidates. |
|
|
|
|
|
|
Nov-22, 2001
9th China-Days, Cologne, Germany – Bicoll presentation |
|
Bicoll invited to talk about recent projects at the 9th China-Days, Cologne
The German Asia Pacific Society, Cologne/Germany, invited Dr. Kai Lamottke to the 9th China Days. Dr. Lamottke gave a presentation on the recent Public-Private-Partnership-project (PPP) of Bicoll Biotechnology (Shanghai) Co. Ltd. in the P.R. China ("Investieren in China mit einem starken Partner: PPP-Projekt Bicoll/DEG"). Bicoll and the German Investment and Development Company (DEG) are currently working together successfully in such a partnership.
About Bicoll
Bicoll was founded in December 2000 as a unique German-Sino start-up biotech company and provides an innovative, flexible and fast concept for modern drug research. By combining research in combinatorial chemistry, screening techniques, natural product chemistry and synthesis, Bicoll's mission is to accelerate the developing process of new drug candidates.
The PPP-project is supporting Bicoll to speed up its growth in China.
|
|
|
|
|
|
|
